全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Core Evidence  2009 

Conivaptan: Evidence supporting its therapeutic use in hyponatremia

DOI: http://dx.doi.org/10.2147/CE.S5997

Keywords: Conivaptan hydrochloride, arginine vasopressin (AVP), hyponatremia, arginine vasopressin (AVP) receptor antagonist

Full-Text   Cite this paper   Add to My Lib

Abstract:

nivaptan: Evidence supporting its therapeutic use in hyponatremia Review (4199) Total Article Views Authors: Melissa Li-Ng, Joseph G Verbalis Published Date June 2009 Volume 2009:4 Pages 83 - 92 DOI: http://dx.doi.org/10.2147/CE.S5997 Melissa Li-Ng, Joseph G Verbalis Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, DC, USA Introduction: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well tolerated nor totally effective, and many are associated with significant adverse effects. Vasopressin receptor antagonists, also known as vaptans, are a new class of agents that now offer an additional treatment option for hyponatremic patients. Conivaptan hydrochloride, a competitive antagonist of vasopressin V1a and V2 receptors, is the first agent in this class to be approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. Aims: This review critically assesses the evidence that support the use of conivaptan for the treatment of patients with euvolemic and hypervolemic hyponatremia. Evidence review conclusion: Conivaptan is effective in raising serum sodium levels in a predictable and safe fashion in euvolemic and hypervolemic hyponatremic patients. Conivaptan provides the first molecularly targeted approach for correcting hyponatremia in hospitalized patients.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133